Search clinical trials for: taxane plus carboplatin

Total 7774 results

Yonsei University

Recruiting

Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)

Breast Cancer

Korea, Republic of
Shanghai Jiao Tong University School of Medicine

Recruiting

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer (TCTN)

Breast Neoplasm

China
Shanghai Jiao Tong University School of Medicine
CSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.

Not yet recruiting

Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer (NeoSTEP)

Triple-negative Breast Cancer
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals

Not yet recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

Neoadjuvant Therapies for HER2+ Breast Cancer

China
Shengjing Hospital

Recruiting

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Breast Neoplasms

China
Ruijin Hospital

Recruiting

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

HER2-negative Advanced Gastric Cancer

China
Eli Lilly and Company

Completed

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Malignant Solid Neoplasm

United States, Puerto Rico
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (GPMOC202)

Ovarian Cancer

Korea, Republic of
Bristol-Myers Squibb

Completed

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Canada, United States
Hebei Medical University Fourth Hospital

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Advanced Breast Cancer | HER2-positive Breast Cancer

China
Bristol-Myers Squibb

Terminated

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Cancer

United States
University of Florida

Recruiting

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Breast Cancer

United States
Shanghai Gynecologic Oncology Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Shanghai Jiao...

Recruiting

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Ovarian Cancer Recurrent

China
Northwestern University
National Cancer Institute (NCI)

Withdrawn

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Bristol-Myers Squibb

Terminated

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Cancer

Netherlands, United States
University of Florida
Prana Therapeutics

Withdrawn

Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients

Breast Cancer
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Non-small Cell Lung Cancer

Spain, Belgium, France, Italy, Netherlands, Canada, United Kingdom, United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Italy, Australia, Poland, Spain
Bayer

Completed

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Canada, France, Germany, United States, Netherlands, United Kingdom
Lund University Hospital
Danish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaborators

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Breast Cancer | Triple Negative Breast Neoplasms

Denmark, Sweden
H. Lee Moffitt Cancer Center and Research Institute
Cortice Biosciences, Inc.

Terminated

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

Brain Metastases | Brain Lesions | Generalized Malignancy, Primary

United States
Bayer

Completed

Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

Breast Neoplasms | Breast Cancer, Metastatic

Germany, Italy, Israel, Poland, Switzerland, United Kingdom, Greece
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Breast Cancer

United States
Bayer

Completed

Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Canada, United States, Germany, Israel
Jonsson Comprehensive Cancer Center
TetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaborators

Withdrawn

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma

United States
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Charite University, Berlin, Germany
Pfizer; Aventis Pharmaceuticals

Unknown

A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage

Small Cell Lung Cancer

Germany
Shanghai Gynecologic Oncology Group
Fudan University; Shanghai Zhongshan Hospital; Shanghai Jiao Tong University...

Completed

First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (AICE)

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Bulky Stage IIIC and IV Epithelial Ovarian Cancer

China
Baohui Han

Completed

Combination of Chemotherapy and Gefitinib as First-line Treatment

Non-Small-Cell Lung Cancer

China
German Breast Group

Terminated

A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer (TABEA)

Breast Cancer

Germany
Instituto Nacional de Cancerologia de Mexico

Recruiting

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

Lung Cancer | Sarcopenia | Toxicity

Mexico
Biocon Biologics UK Ltd

Not yet recruiting

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Sai Life Sciences

Completed

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Solid Tumors

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Floor Backes

Terminated

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Lynch Syndrome | Recurrent Endometrial Carcinoma | Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Mismatch Repair Deficiency | Recurrent Uterine Corpus Carcinosarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Lymphadenopathy | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Prostate Small Cell Carcinoma

United States
James Elder

Completed

Carboplatin in Treating Patients With Recurrent High-Grade Gliomas

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Recurrent Adult Brain Tumor

United States
Shanghai Chest Hospital

Unknown

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Pulmonary Large Cell Neuroendocrine Carcinoma
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
New Mexico Cancer Care Alliance

Completed

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

Supportive | Ill-defined Sites

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Haukeland University Hospital

Recruiting

Biomarker Guided Treatment in Gynaecological Cancer (Momatec2)

Endometrial Cancer

Norway, Netherlands, Poland
University of Washington
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Centre Hospitalier Universitaire de Besancon

Completed

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients (TandHER)

Metastatic Cancer | HER2-positive Gastric Cancer | Docetaxel | Trastuzumab

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC... and other conditions

United States

Search clinical trials for: taxane plus carboplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations